Danaher pays $180/share for Masimo in $9.9B deal—a 40% premium. Masimo stock surges 34% while DHR drops 6% on integration concerns.

Danaher Acquires Masimo for $9.9 Billion in Largest Medtech Deal of 2026

Danaher agrees to buy Masimo for $9.9B at $180/share—a 38% premium. Deal ends activist battle, Apple patent war backdrop. Closes H2 2026.

Danaher to Acquire Masimo for $9.9 Billion in Cash, Ends Turbulent Chapter

Danaher acquires Masimo for $9.9B at $180/share, a 38% premium. Deal strengthens diagnostics segment with pulse oximetry leader.

Danaher nears $10B Masimo acquisition at 43% premium. Life sciences giant expands into patient monitoring after signaling M&A readiness.